Boerhinger Ingelheim grows cancer care product line by buying NBE Therapeutics
… Boerhinger Ingelheim buys oncology therapy innovator NBE Therapeutics …

Boehringer Ingelheim Acquiring NBE Therapeutics For $1.5 Billion

NBE Therapeutics’ novel oncology clinical technology is sought by Boehringer Ingelheim to boost new cancer drug development pipeline

  • $398 million for AMAL Therapeutics (immunotherapies and oncology vaccines developed through its proprietary KISIMA platform) in 2019
  • $257 million for Vira Therapeutics (oncolytic cancer-destroying viruses and specifically its proprietary oncolytic virus, VSV-GP) in 2018

NBE product pipeline details

  • Exelixis, a genomics-focused enterprise based in Alameda, California
  • SOTIO, an immunotherapy biotechnology company headquartered in Prague, Czech Republic

Boehringer seeks to build out its oncology business unit

  • Cancer cell-directed therapies
  • Immune cell-directed therapies.

A global competitor in multiple biotech and pharmaceutical market sectors

  • Cardiovascular
  • Central Nervous System (CNS)
  • Immunology
  • Metabolic
  • Oncology
  • Respiratory
  • Retinal
  • Companion animal and livestock veterinary medicines
  • Biopharmaceutical contract manufacturing

2020 has been a busy year for companies doing business in cancer care

Licensing and merger & acquisition deals are pivotal strategies of pharma and diagnostic companies competing in oncology

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Bare Sky Marketing — Healthcare Content Writing

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/